(Total Views: 349)
Posted On: 04/14/2020 7:05:51 PM
Post# of 36570
If NGIO's technology is the real deal as Joe has stated repeatedly, the headline should have read:
"Generex Biotechnology plans to file for Emergency Use Authorization(EUA) with the FDA for mass public vaccination this coming Fall.
Provides Update on the Development of an
Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic."
That headline would have gotten the market's attention.
"Generex Biotechnology plans to file for Emergency Use Authorization(EUA) with the FDA for mass public vaccination this coming Fall.
Provides Update on the Development of an
Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic."
That headline would have gotten the market's attention.
(1)
(0)
